Gal1-neutralizing mAb 8F4F8G7 inhibits Gal1-mediated apoptosis of EBV-specific CTLs. (A) EBV-specific CTLs were treated with rGal1 alone or with rGal1 preincubated with αGal1 mAb or isotype control for 4 hours. The percentage of viable CD8⁺ CTLs (7AAD⁻) is shown at the top of the gate. (B) The histogram summarizes the percentage of viable, EBV-specific, CD8⁺ CTLs after the indicated treatments.